In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis  by Noronha, Irene L. et al.
Kidney International, Vol. 43 (1993), pp. 682—692
In situ production of TNF-a, IL-1f3 and IL-2R in ANCA-
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IRENE L. NORONHA, CORNELIA KRUGER, KONRAD ANDRASSY, EBERHARD RITZ,
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In situ production of TNF-a, IL-1j3 and IL-2 receptors in ANCA-
positive glomerulonephritis. Humoral and cellular immune mechanisms
are thought to be involved in various forms of vasculitis and glomeru-
lonephritis. Recent clinical and experimental results point to a role of
cytokines in ANCA-positive vasculitides. We analyzed tumor necrosis
factor-a (TNF-a), interleukin-l/3 (IL-l/3) and interleukin-2 receptors
(IL-2R) in renal biopsies and in plasma from 22 patients with Wegener's
granulomatosis and microscopic polyangiitis. Kidney biopsies were
examined by immunocytochemistry, polymerase chain reaction and in
Situ hybridization. Immunoreactjve TNF-a, IL-l/3 and/or IL-2R posi-
tive infiltrating cells were observed in 21 of 22 biopsies. TNF-a, IL-1f3
and IL-2R staining was evident in the interstitium and at periglomerular
and perivascular sites. The number of positive cells was markedly
increased in biopsies with active lesions. Positive cells were also
present in cellular and fibrocellular crescents, surrounding tuft necrosis
and in the walls of arteries and arterioles with acute vasculitic lesion.
Some tubular epithelial cells stained for TNF-a and IL-l/3. TNF-a,
IL-l$ and IL-2R positive infiltrating cells correlated with the presence
of histologically active renal lesions. The evaluation of TNF-a and
IL-l13 expression at the mRNA level assessed by the polymerase chain
reaction demonstrated specific transcripts for TNF-a and IL-lf3 in all
six cases analyzed. in situ hybridization studies showed an increased
expression of mRNA for TNF-a and IL-l/3 in infiltrating mononuclear
cells, in epithelial cells of Bowman's capsule and in some tubules,
predominantly of patients with active renal lesions. The results at the
mRNA level correlated with the immunocytochemical findings. Com-
pared to healthy individuals higher TNF-a plasma levels were observed
in patients with vasculitis (34.4 16.6 pg/ml (5EM) vs. 1.9 0.7 pg/mI
in controls; P < 0.01). All patients presented a marked increase in
sIL-2R plasma levels (3512 485 U/mi vs. 397 21 U/mI in healthy
controls; P < 0.001). IL-l/3 was not detected in most plasma samples.
Elevated TNF-a and sIL-2R plasma levels were related to active renal
lesions. Our study clearly demonstrates that in ANCA-positive vascu-
litis TNF-a and IL-I 3 are produced in situ by activated infiltrating
mononuclear cells and resident renal cells. Intrarenal localization of
cytokine producing cells and the correlation between cytokine produc-
tion and histological signs of activity suggest that TNF-a and IL-I j3 are
important locally acting mediators in the vasculitic/glomerulonephritic
process.
The precise pathogenesis of systemic vasculitis is largely
unknown. The demonstration and further characterization of
circulating anti-neutrophil cytoplasmic autoantibodies (ANCA)
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in some patients with vasculitis was of critical importance not
only for diagnosis and classification but also as a marker of
disease activity [1—8]. The development of a necrotizing inflam-
matory vasculitic lesion, however, seems to be a complex
process involving not only humoral but also cell-mediated
immune reactions.
In cellular immune reactions the IL-2 receptor (IL-2R) plays
a central role since the interaction of IL-2 with its receptor is a
prerequisite for clonal T-cell proliferation. IL-2R is not only
expressed on the cell membrane, but also released into the
extracellular fluid. Concomitantly, cytokines are produced and
recent studies have provided substantial evidence that they are
important mediators of inflammation in ANCA-positive vascu-
litis [9—il]. In this context, the most relevant cytokines are
tumor necrosis factor-alpha (TNF-a) and interleukin-1f3 (IL-
1/3). These cytokines can be produced either by cells of the
monocyte/macrophage lineage or by endothelial cells (EC) and
vascular smooth muscle cells [12—14]. TNF-a and IL-l/3 have
strong proinflammatory and procoagulant effects. Cytokine
stimulated EC have the ability to produce inflammatory factors,
such as PAF [15] and prostaglandins, and, in addition, they
induce procoagulant activities through production of plasmino-
gen activator inhibitor [161 and/or decreasing endothelial sur-
face thrombomodulin [17]. Furthermore, TNF-a and IL-i can
induce de novo expression of EC-leukocyte adhesion molecules
(such as ICAM-l, ELAM-l, and VCAM-1) facilitating the
adhesion and attachment of polymorphonuclear leukocytes
(PMN) [18-.-21}.
The activation of PMN plays a central role in vasculitic
reactions. Falk and coworkers [10] demonstrated that priming
of human neutrophils in vitro with TNF-a induces the expres-
sion of ANCA antigens such as myeloperoxidase on the cell
surface of PMN. The interaction of these antigens with ANCA
antibodies activates the neutrophils via signal transduction
pathways [22] resulting in degranulation with release of pro-
teases and oxygen radicals. Furthermore, in vitro anti-my-
eloperoxidase antibodies stimulate neutrophils to damage um-
bilical vein endothelial cells primed with TNF-a [11].
In order to evaluate the potential role of TNF-a, IL-1J3 and
IL-2R in systemic vasculitis, we analyzed these molecules in
kidney biopsies and in plasma of patients with ANCA-positive
vasculitis (Wegener's granulomatosis and microscopic poly-
angiitis). We demonstrate that these factors are produced in situ
at sites of inflammation. Our findings strongly support the
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hypothesis that TNF-a and IL-1$ are important mediators in
the development of the vasculitic/glomerulonephritic lesions.
Methods
Patients
Twenty-two patients with ANCA-positive systemic vasculitis
and renal involvement were included in this study (8 males, 14
females; median age 58 years, range 10 to 74 years). Patients
with systemic lupus erythematosus, Churg-Strauss syndrome,
Schönlein-Henoch purpura, and classic polyarteritis nodosa
were excluded. They have been cared for by the renal unit of
the University of Heidelberg and have been submitted to renal
biopsy between April 1988 and May 1990.
Based on both clinical and pathological features the patients
were diagnosed as Wegener' s granulomatosis (WG) or micro-
scopic polyangiitis (MPA). As described elsewhere [23], diag-
nostic criteria for Wegener's granulomatosis included the pres-
ence of a granulomatous inflammation with vasculitis in the
upper and/or lower respiratory tract and the presence of pauci-
immune necrotizing/crescentic glomerulonephritis (GN).
Twelve patients fulfilled these criteria. Two additional patients
with the typical extrarenal findings had only focal-segmental
GN. The presence of circulating ANCA was analyzed by
indirect immunofluorescence [23]. All patients had a diffuse
granular cytoplasmic ANCA pattern (C-ANCA) and proteinase
3 antibodies by ELISA. MPA (N = 7) was characterized by
clinical and morphological evidence of systemic small vessel
vasculitis (affecting arterioles, venules and capillaries) as well
as necrotizing/crescentic GN without granuloma formation. All
patients exhibited a perinuclear staining pattern of ANCA
(P-ANCA) on indirect immunofluorescence and had MPO anti-
bodies by ELISA. One patient (No = 11) with C-AN CA could
not be classified definitively. In another patient (No = 5) with
typical signs of WG, ANCA could not be determined for
technical reasons. The patient was treated and followed in
another hospital. He responded promptly to immunosuppres-
sive therapy and subsequent ANCA tests were negative.
The patients were categorized according to the presence or
absence of active histological lesions. Active lesions included
glomerular and vascular fibrinoid necrosis, cellular or fibrocel-
lular crescents, and marked periglomerular and perivascular
inflammatory infiltrates. Inactive lesions comprised glomerular
sclerosis (segmental or global), fibrous crescents, interstitial
fibrosis and tubular atrophy with minor interstitial infiltrates
and vascular scarring. All patients were treated with cyclophos-
phamide and high doses of steroids according to the protocol
described elsewhere [23]. In 11 patients renal biopsies (6 with
active, 5 with inactive lesions) were performed prior to the
immunosuppressive treatment. In 11 cases renal biopsies were
obtained after initiation of treatment (3 to 40 days; 5 active, 6
inactive). The most relevant clinical, histological and laboratory
data are summarized in Table 1.
Renal biopsies
Percutaneous needle biopsies were analyzed by light and
immunofluorescence microscopy as described elsewhere [24].
For conventional immunofluorescence microscopy and immu-
nocytochemistry the biopsy specimen was embedded in Tissue
Tek, immediately snap frozen in liquid nitrogen and stored at
—70°C until use. Cryostat sections of 4 m thickness were cut,
air dried and fixed in acetone at 4°C.
Eight biopsies were suitable for in situ hybridization studies.
Seven im thick sections were cut and mounted onto slides
coated with 2% aminopropyltriethoxylane (Sigma Chemical
Co., St. Louis, Missouri, USA) in acetone. Sections were fixed
in freshly prepared 3% neutral buffered paraformaldehyde with
0.02% diethylpyrocarbonate (DEPC, Sigma) for five minutes at
room temperature, dehydrated in 70%, 95% and absolute etha-
nol, air dried and stored with desiccant at —70°C until use.
Total RNA was extracted in six cases from the remaining
biopsy tissue and processed for reverse transcription and the
polymerase chain reaction,
Immunocytochemical technique
In brief, the sections were incubated with monoclonal anti-
bodies to TNF-a (Celltech CB 0006, Berkshire, UK) and IL-2R
(CD25; Clonab TO 69, Biotest Diagnostics, Dreieich, Germany)
at optimal dilutions, In selected cases sequential sections were
incubated with monoclonal antibodies to macrophages (CD68;
KP1; Dakopatts, Copenhagen, Denmark) and CD3 (Leu4: Bec-
ton-Dickinson, Mountain View, California, USA). After wash-
ing, the sections were incubated with rabbit anti-mouse immu-
noglobulin (Dakopatts). To complete the sandwich technique,
an incubation with a soluble complex of alkaline phosphatase
anti-alkaline phosphatase (APAAP; Dakopatts) was performed.
The last two steps were repeated twice to enhance the intensity
of the reaction product. Finally, the slides were incubated with
a freshly prepared substrate, consisting of naphthol AS-MX-
Phosphate (Sigma Chemical Co.) and fast red dye (Sigma
Chemical Co.). The slides were counterstained with Mayer's
haemalaum and covered with glycerin-gelatine. Immunohisto-
chemical study for IL-l/3 was performed using a polyclonal
rabbit antibody (Genzyme Co., Cambridge, Massachusetts,
USA). The following steps comprised an intermediate incuba-
tion with mouse anti-rabbit immunoglobulins, and subse-
quently, with rabbit anti-mouse immunoglobulin and the
APAAP complex. Normal human kidney tissue obtained from
patients with tumor nephrectomies (N = 5) served as controls.
Control experiments were carried out in each case by omitting
the incubation with the first monoclonal antibody. Positive
controls were carried out by analyzing the staining of human
blood mononuclear cells in culture after stimulation with lipo-
polysaccharide (LPS) or phytohemagglutinin (PHA) [25]. The
number of immunoreactive cells in biopsy specimens were
scored as follows: 0 no positive cells, 1 + scattered positive cells
and 2+ numerous positive cells.
Reverse transcription/polymerase chain reaction (RT/PCR)
Total RNA was isolated using the guanidinium thiocyanate
method, described by Chomczynski et al [26]. Biopsies were
homogenized with a solution containing 4 M guanidinium thio-
cyanate, 25 m sodium citrate pH 7.0, 0.5% sarcosyl and 0.1 M
p-mercaptoethanol and extracted with water-saturated phenol.
RNAs were precipitated with isopropanol and washed with
ethanol. The quality of the RNA was controlled on a 1%
agarose gel in 3-N morpholinopropanesulfonic acid buffer
(MOPS-buffer).
One ig of total RNA was reverse transcribed into cDNA
using either downstream primers (0.75 M of 3'-sequence
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Table 1. Pertinent clinical, histological and laboratory data of patients with ANCA-positive systemic vasculitis
N Age/sex Diagnosis Organ involvement Renal involvement
Crescents/
necrosis
(%)b
Glom.
obsolesc.
(%)
Sara
(mgldl)
ANCA ANCA
titer° patterna
Active
I 40/F WG L, N, E, M cresc. GN 50 — 4,5 1:80 C-ANCA
2 49/M WG L, N, E, Y, S, A cresc. GN 70 — 2,5 1:40 C-ANCA
3 46/M WG L, N, F, Y, NS necrot. and cresc. GN 65 10 1,4 1:320 C-ANCA
4 55/F WG N, A, NS necrot. and cresc. GN 80 — 2,4 1:80 C-ANCA
5 68/F WO N, A necrot. and cresc. ONC 100 — 7,2 Not done
6 hIM WG L, N, Y, T necrot. and cresc. ON° 100 — 5,0 1:320 C-ANCA
7 63/F WG L, N, Y, A necrot, and cresc. ON 100 — 3,1 1:320 C-ANCA
8 59/M MPA L, N, A cresc. GN 10 10 1,6 1:320 P-ANCA
9 57/F MPA L, N cresc. ON 100 — 2,8 1:160 P-ANCA
10 63/F MPA L, N, Y, To, A necrot. and cresc. ON 100 — 3,0 1:80 P-ANCA
11 61/F MPA/WG A, NS cresc. ON 65 — 2,2 1:160 C-ANCA
Inactive
12 72/M WO L, N, Y, S focal-segmental ON — 25 1,4 1:60 C-ANCA
13 10/F WO N, S, A, Oh, Y cresc. ON 30 20 1,5 1:40 C-ANCA
14 62/M WO L, N, Y, A selerosing ON — 65 2,9 1:40 C-ANCA
15 48/M WG L, N, E, S, A sclerosing ON — 80 5,2 1:160 C-ANCA
16 67/F WG L, N, E, A cresc. ON 50 25 1,6 1:160 C-ANCA
17
18
58/F
50/F
WO
WO
L, N, E, A
L, A
sclerosing ON
focal-segmental ON
—
10
80
10
2,2
0,5
1:40 C-ANCA
1:1280 C-ANCA"
19 48/F MPA L, N, H, S, A cresc. ON 10 — 1,0 1:160 P-ANCA
20 62/F MPA L, Y, A cresc. ON 30 70 1,9 1:160 P-ANCA
21
22
63/F
74/M
MPA
MPA
L, GI, S, H, Y, A, NS
N, NS
sclerosing ON
cresc. ON
—
40
35
20
1,3
2,7
1:160 P-ANCA
1:1280 PANCAd
Patients were classified as having active or inactive histological lesions according to the criteria described in Methods
Abbreviations are: L, lung; N, nose/sinus; Y, eyes; E, ear; S, skin; A, arthralgiaiarthritis; H, heart; GI, gastro-intestinal; NS, nervous system;
M, mouth; To, tonsils; T, tooth granuloma; cresc., crescentic; necrot., necrotizing; obsolesc., obsolescence.
a At time of renal biopsy.
ID In patients with active lesions, the percentage refers to the number of glomeruli per biopsy specimen with cellular or fibrocellular crescents
and glomerular loop necrosis. In inactive ON, crescents were poorly fibrous without proliferation or necrosis.
C Presenting with a diffuse "granulomatous" ON.d Presenting with inactive renal disease but active extrarenal symptoms.
Table 2. 5' and 3' oligonucleotide primers of TNF-a, IL-l$ and J3-actin genes and corresponding internal oligonucleotide probes
Size of
the PCR
3' primers product
5' primers (sense) (antisense) (bp) Internal oligonucleotide probes
TNF-a 5'-CAG AOO OAA GAO TTC CCC 5'-CCT TOO TCT OGT AOO 325 5'-CTr GAG GOT TTO CTA CAA CAT
AG-3' AOA CG-3' GGO-3'
IL-1/3 5'-AAA CAO ATG AAG TOC TCC 5'-TGO AGA ACA CCA CTT 388 5'-GAT AOG TTC TTC TTC AAA OAT
TTC CAO 0-3' OTT GCT CCA-3' 0-3'
/3-actin 5'-ATC ATG TTT GAG ACC TTC 5'-CAT CTC TTG CT CGA 318 5'-GAC CTG OCT OOC CCG OAC CTG
AAC A-3' AGT CCA-3' ACT GAC TOA C-3'
specific primers) or oligo(dT) [0.5 /LM oligo(dT)J and 200 U
M-MLV reverse transcriptase (Gibco-BRL) at 37°C for one
hour in a volume of 20 l containing 30 to 50 mrvi Tris-HCI pH
8.3, 50 to 75 mas KCI, 10 mt DTT, 3 to 5 mrvi MgCl2, I mM each
dATP, dCTP, dGTP, dTTP and 10 U RNase inhibitor from
human placenta (Gibco-BRL, Eggenstein, Germany).
The PCR was carried out using specific primers (15 pmoles of
each primer), 2.5 U of AmpliTaq DNA polymerase (Perkin-
Elmer-Cetus, Norwalk, Connecticut, USA) in a 100 1.d final
reaction containing 2 mri MgCI2, 60 mtvi KCI, 12 m Tris-HC1
pH 8.3. Forty cycles of PCR amplification were performed
using a Thermocycler 60 (Bio-med, Theres, Germany). Each
cycle consisted of a denaturation step of one minute at 95°C,
followed by one minute annealing at 59°C for TNF-a, 67°C for
IL-1f3, and 55°C for /3-actin. The final product was extended for
seven minutes.
The TNF-a-primers (Table 2) amplified a fragment of 325 bp.
The IL-1f3-specific primers amplified a fragment of 388 bp. As
positive control /3-actin-specific primers were used which am-
plified a fragment of 318 bp. The resulting fragments were
electrophoresed on a 2% agarose-gel in TBE-buffer. Southern
blots were performed to further confirm the specificity of the
PCR-positive bands. The electrophoresed PCR products were
blot-transferred onto a nylon membrane (Schleicher & Schuell
Nytren-N, Dassel, Germany), and the filters were baked at 80°C
for two hours. The filters were prehybridyzed in 10 ml of 10 x
Denhardt's solution, 6 X SSC, 0.5 mg/ml salmon-sperm DNA
for two hours at room temperature, and then hybridyzed
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overnight in the same buffer containing 32P-labeled oligonucle-
otides (listed in Table 2) which were labeled at the 5' end using
polynucleotide kinase (New England Biolabs, Inc., Beverly,
Massachusetts, USA). Filters were washed twice in 6 x stan-
dard saline citrate solution (SSC) at room temperature and then
in 6 x SSC with 1% SDS at 60°C and autoradiographed with
intensifying screens at —70°C.
RNA preparations of PHA stimulated cells of the THP-1
monocytic cell line served as positive control.
In situ hybridization
The in situ hybridization procedure was based on the proto-
col described by Shivers et al [27], with some modifications. All
solutions were RNase free, and in addition, treated with RNase
inhibitor (0.1% DEPC), except for TRIS buffers and triethanol-
amine solutions.
The slides were brought to room temperature and rehydrated
in 5 mivt MgC12 in PBS. They were subsequently immersed in
0.1 N HC1, 10 minutes and washed in PBS. Finally, the sections
were acetylated in freshly added acetic anhydride (0.25%) with
0.1 M triethanolamine, pH 8. They were rinsed in PBS and
dehydrated sequentially in graded alcohols.
Probes were transcribed in vitro (SP6/T7 transcription kit,
Boehringer Mannheim, MA, Germany) from plasmids contain-
ing an IL-1f3 cDNA fragment (pSPhIL-1/3.2, Alan Shaw, Glaxo
Institute, Geneve, Switzerland). TNF-a-cDNA probe (J.
Browning, Biogen, Inc., Cambridge, Massachusetts, USA) was
subeloned into the polylinker site of the transcription vector
PGEM-1 (Promega Biotech, Madison, Wisconsin, USA) using
T4 ligase and standard cloning techniques. After linearization of
the templates with the appropriate restriction enzymes, sense
and antisense riboprobes were generated, using SP6 and T7
polymerases (all enzymes from Boehringer Mannheim). They
were labeled with [a35S]-uridine triphosphate (Amersham) to a
specific activity of approximately 1-2 x l0 cpm/tg.
The final hybridization mixture contained the 355-iabeled
riboprobe (2 x 106 cpmlsection), 50% formamide, lx Den-
hardt's solution, 10% dextran sulfate, yeast tRNA (500 tg/ml),
sheared salmon sperm DNA (500 jsg/ml), 10 mrvi TRIS pH 7.5,
1 mri EDTA and 10 mivi DTT. The mixture was heated at 95°C
for two minutes and then placed at 55°C. Twenty d of hybrid-
ization mixture were applied to each section. The sections were
covered with a siliconized coverslip and incubated overnight at
55°C in a humid chamber.
Following hybridization, the slides were washed briefly in 4
x SSC, 2 x SSC and 1 x SSC, at 42°C, and with a RNase
solution (10 g/ml RNase A and 1 U/ml RNase Tl; Sigma) at
37°C for 30 minutes. The sections were subsequently washed in
2 x SSC and incubated in 2 x SSC/0.l% p mercaptoethanol at
42°C, two changes of 15 minutes each, and in I x SSC/0. 1% f3
mercaptoethanol at 60°C, two changes of 20 minutes each.
Finally, the slides were immersed in 0.5 x SSC/0.1% /3 mer-
captoethanol and incubated at a minimum of one hour at room
temperature. The sections were then dehydrated in graded
ethanol containing 300 mr.i ammonium acetate and air dried.
Autoradiography was performed by dipping the slides into
Kodak-NTB2 nuclear track emulsion (Kodak) diluted 1:1 with
600 mM ammonium acetate at 42°C, under safelight conditions
and dried overnight. The slides were packed in black boxes,
stored at +4°C, and exposed for five days. The autoradiograms
were developed in Kodak Dl9 developer and fixed in Kodak
Fix. Finally, sections were counterstained with hematoxylin-
eosin and coverslipped with Permount mounting medium.
Controls consisted of in situ hybridization of the sense and
antisense probes with peripheral blood mononuclear cells stim-
ulated with LPS, known to express TNF-a and IL-1/3 mRNA.
Negative controls were carried out by hybridizing sections with
the corresponding sense probes. In addition, in situ hybridiza-
tion was performed with sections pretreated with RNase.
The sections were analyzed under dark field illumination to
give a general appreciation of the distribution pattern of labeled
cells at low power. Light microscopic analysis permitted a
morphological examination and evaluation of the presence,
localization and distribution of increased silver grains. Sections
were scored by comparing them with normal renal tissue and
with matched sections hybridized with the sense probe. The
background varied within the different experiments. Positivity
was assessed when the number of grain counts was at least four-
to fivefold higher than background and by comparing with sites
such as urinary space or vessel lumen where almost no silver
grains were detected.
ELISA assays
TNF-a, IL- 1/3 and the soluble form of IL-2R (sIL-2R) plasma
levels from 18 patients were assayed by means of commercial
sandwich ELISAs (Biokine TNF and sIL-2R, T-Cell Sciences,
Cambridge, Massachusetts, USA; IL-113, Quantikine, R&D
Systems, Minneapolis, Minnesota, USA). The analyzed sam-
ples were obtained at the time of renal biopsy. All analysis were
performed at the same time to avoid repeated thawing and
freezing of plasma samples. Briefly, the first monoclonal anti-
body was coated on polystyrene microtiter plate wells. Fifty d
of standards or plasma samples were added and incubated for
two hours at 37°C. The wells were washed and incubated with
a second monoclonal antibody (directed against a second
epitope) conjugated with horseradish peroxidase. After two
hours at 37°C, the wells were washed and a substrate solution
composed of o-phenylenediamine was applied. The reaction
was stopped with 2 N sulfuric acid and absorbance was mea-
sured at 490 or at 450 nm using an ELISA reader (Titertek
Multiskan Plus, Meckenheim, Germany). A standard curve was
prepared from standards and the sample values were deter-
mined by means of a computer program (EIA-Microsoft,
Dynatech, Chantilly, Virginia, USA). Values were expressed as
pg/ml for TNF-a and IL-l/3 and as units/mi (U/ml) for sIL-2R.
The control group for the determination of TNF-a, IL- 1(3 and
sIL-2R levels consisted of 30 age matched healthy blood
donors.
Statistical analysis
Data were expressed as mean and standard error of mean
(sEM). Statistical comparisons between values were made by
the Wilcoxon rank-sum test. Correlation coefficients were
tested for significance using the Spearman rank test.
Results
Immunocytochemistry
The immunocytochemical results are summarized in Table 3.
No TNF-a, IL-lf3 and IL-2R staining was observed in control
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Fig. 1. TNF-a immunoreactivity in crescentic glomerulonephritis of a patient with Wegener's granulomatosis. TNF-a positive cells are present
in extracapillary proliferates and in periglomerular localization (x 240).
Fig. 2. TNF-a positive cells in acute intrarenal arteriolitis in a patient with microscopic polyangiitis (X 360).
Fig. 3. Glomerular IL-i f3 immunoreactivity in a biopsy from a patient with microscopic polyangiitis. The positive reaction is observed in
proliferating capsular epithelial cells and infiltrating glomerular and periglomerular mononuclear cells corresponding to CD68-positive monocytes/
macrophages (x 240).
Fig. 4. lL-2R positive interstitial infiltrates in a patient with microscopic polyangiitis (X 240).
Fig. 5. Biopsy from a patient with Wegener's granulomatosis. Note the presence of IL-2R positive mononuclear cells within a crescent, in
periglomerular localization and occasionally in capillary lumina (x 240).
Fig. 6. In situ hybridization (autoradiogram) using a 35S-labeled IL-i /3 antisense riboprobe (biopsy from a patient with microscopic polyangiitis).
IL-l/3 mRNA is expressed in periglomerular infiltrating cells, and in cells of a segmental crescent (X 240).
Fig. 7. In situ hybridization (autoradiogram) using 35S-labeled TNF-a antisense riboprobe (biopsy from a patient with microscopic polyangiitis).
Marked TNF-a mRNA is expressed in cells surrounding fibrinoid tuft necrosis (X 360).
Fig. 8. In situ hybridization (autoradiogram, dark field microscopy) using a 35S-labeled TNF-a antisense riboprobe (biopsy from a patient with
Wegener's granulomatosis). Note the expression of TNF-a mRNA by tubular epithelial cells corresponding to a distal tubule on light microscopy
and by surrounding infiltrating cells (x 940).
Table 3. TNF-a, IL-1f3 and IL-2R positive cells in renal biopsies (N = 22) detected by immunocytochemistry (score, see Methods)
Interstitum Glomeruli Tubules Vessels
0 1+ 2+ 0 1+ 2+ 0 1+ 2+0 1+ 2+
TNF-a 1 9 12 5 9 8 18 3 1 3 9 10
IL-l/3 1 15 6 10 6 6 9 10 3 18 4 0
IL-2R 2 8 12 15 5 2 22 0 0 22 0 0
Table 4. TNF-a, IL-1/3 and IL-2R positive cells (immunocytochemistry) in biopsies with active (N = 11) and inactive lesions (N = 11)
Active Inactive
Interstitium Glomeruli
0
Interstitium
1+ 2+
Glomeruli
0 1+ 2+ 0 1+ 2+ 0 1+ 2+
TNF-a
IL-l/3
IL-2R
1
1
0
2
4
3
8
6
8
1
1
7
4
4
2
6
6
2
0
0
2
7
11
5
4
0
4
4
9
8
5
2
3
2
0
0
kidneys. In contrast, infiltrating mononuclear cells stained for
TNF-a were found in 21 of 22 biopsies. Positive cells were
scattered throughout the interstitium or were localized in
perivascular sites. TNF-a positive cells were numerous, that is
score 2+, in 12 of 22 cases and scarce, that is score 1+, in nine
cases. All biopsies but one with active lesions (Table 4) showed
marked TNF-a staining. TNF-a positive cells were seen within
the glomeruli in 17 of 22 biopsies (Table 3) particularly sur-
rounding loop necrosis; in addition, strong TNF-a immunore-
activity was observed in many cells of cellular and fibrocellular
crescents (Fig. 1) and was faintly observed in endothelial cells
(EC). TNF-a positive cells were also present in the walls of
arteries and arterioles bearing active vasculitic lesions (Fig. 2).
Smooth muscle cells of arterial and arteriolar walls stained
faintly positive. In four cases, epithelial cells of some proximal
and distal tubules showed positive TNF-a staining.
IL-l3 positive infiltrating cells were observed in 21 of 22
cases. They were present in the interstitium. They also sur-
rounded and occasionally infiltrated blood vessels, a pattern
comparable to the one noted for TNF-a positive cells. IL-l/3
positive cells were detected in the glomeruli of 10 of 11 cases
with histological signs of active renal lesions (Table 4, Fig. 3).
Cells of Bowman's capsule were strongly positive. Weak IL-1f3
immunostaining was observed in the arterial vessel wall of four
cases. Tubular epithelial cells disclosed weak reactivity, partic-
ularly in some distal tubules. No IL- 1/3 staining was noted in
mesangial areas.
IL-2R positive mononuclear cells in the interstitium were
detected in 20 of 22 biopsies (Table 3, Fig. 4). Both cases with
negative staining were inactive (Table 4). IL-2R positive cells
were also distributed in periglomerular and perivascular areas.
Infiltrating cells expressing IL-2R were also localized in cellular
crescents (Fig. 5). In seven of 22 biopsies a few intraglomerular
IL-2R positive cells were observed. No IL-2R positive cells
were present in the vessel walls. IL-2R staining was observed in
casts, probably as a result of filtered IL-2R (soluble form).
Interepithelial IL-2R positive infiltrating cells in tubular walls
were observed in five cases.
z (
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4
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There was a correlation between the number of TNF-a,
IL-l/3 and IL-2R positive infiltrating cells and the presence of
histologically active renal lesions (Table 4) but no significant
differences between patients receiving treatment or not at the
time of biopsy. In glomeruli, infiltrating macrophages and
proliferating capsular epithelial cells were the predominant cells
expressing TNF-a and IL-lf3. In the only negative case renal
biopsy was performed very early after onset of the disease. The
monocyte-macrophage infiltrate in this case, analyzed with an
anti-macrophage monoclonal antibody (CD-68) was scarce. No
difference was observed between cases classified as WG or
MPA with respect to the cytokine expression in renal biopsies
except for the presence of more TNF-a, IL-l/3 and IL-2R
positive cells in WG with diffuse granulomatous GN (see Table
1).
When analyzing sequential sections stained for CD68 and
CD3, the majority of TNF-a and IL-i 13 positive infiltrating cells
corresponded to monocytes/macrophages whereas cells ex-
pressing IL-2R were positive for CD3.
In situ hybridization
In situ hybridization studies showed no TNF-a and IL-1$
transcripts in normal renal tissue. In contrast, all eight biopsies
from patients with vasculitis that were available for analysis
exhibited marked expression of TNF-a and IL-113 mRNA. This
was predominantly found in patients with active lesions. Clus-
ters of silver grains corresponding to TNF-a and IL-l/3 tran-
scripts were observed in infiltrating mononuclear cells. They
were particularly prominent in perivascular and periglomerular
infiltrates (Fig. 6). There was also a marked TNF-a and IL-l/3
mRNA expression in cells surrounding fibrinoid glomerular
necrosis and in crescents (Fig. 7). Numerous positive cells
corresponding to proliferating epithelial cells and CD68 positive
monocytes/macrophages were present in cellular crescents and
less in fibrocellular crescents. Furthermore, TNF-a and IL-lfi
mRNA expression was noted in cells of some proximal and
distal tubules (Fig. 8). In arteries and arterioles TNF-a and
IL-l/3 mRNA was seen in endothelial cells, smooth muscle cells
and pericytes. In acute vascular necrotizing lesions, areas of
necrosis were negative but were surrounded by a dense inflam-
matory infiltrate which strongly expressed TNF-a and IL-lf3
mRNA.
Sections hybridized with sense riboprobes or tissue treated
with RNase prior to hybridization showed no significant grain
counts and were scored as negative.
Reverse transcription/polymerase chain reaction
Figure 9 illustrates the results of cytokine mRNA expression
in renal biopsies analyzed by RT/PCR using specific TNF-a
(Panel A), IL-1f3 (Panel B) and /3-actin (Panel C) primers. The
upper part of the figure shows ethidium bromide staining of the
PCR products separated on a 2% agarose gel. The lower part
shows the respective Southern blot hybridization analysis of the
cytokine products.
Panel A presents the results using TNF-a specific primers.
Fragments of the expected length (325 bp) were detected in all
cases. Southern blotting with subsequent hybridization with a
TNF- oligonucleotide probe confirmed the specificity of the
PCR products in all cases.
Panel B shows mRNA for IL-l/3 in cases one to five. No
transcripts were detected in two biopsies (lanes 6 and 7).
Southern blot hybridization analysis of PCR products con-
firmed the strand specificity, even in cases six and seven, which
were negative when analyzed on agarose gel electrophoresis.
Panel C illustrates f3-actin transcripts (positive controls) in all
RNA preparations analyzed.
TNF-a, IL-I /3 and sIL-2R plasma values
Healthy individuals showed consistently low or undetectable
TNF-a levels. High TNF-c plasma levels were observed in 13
patients with vasculitis. The mean plasma value of TNF-a in
patients (N = 18) with vasculitis was 34.4 16.6 pg/ml
compared to 1.9 0.7 pg/mi in the control group (N = 30; P <
0.01). Patients with active lesions presented significantly higher
TNF-a levels (N = 7; 75.9 38.7 pg/mI) than patients with
inactive lesions (N = 11; 8.1 4.4 pg/mi; P < 0.05). Compared
to healthy controls, all patients had a marked increase in sIL-2R
plasma levels (3512 485 vs. 397 21 U/mi in healthy controls;
P < 0.001). Higher sIL-2R levels were found in patients with
active vasculitis (N = 7) than in patients with inactive lesions
(N = 11; 4470 789 vs. 2556 428 U/mi; P <0.05). There was
no correlation between TNF-a and sIL-2R plasma levels and
actual serum creatinine. Non-treated patients had higher
plasma levels than patients who received immunosuppressive
treatment at the time of biopsy. This difference, however, was
not significant. Elevated IL-l/3 (18, 19 and 118 U/mi) was found
in three patients with vasculitis, whereas it was undetectable in
the remaining cases.
Discussion
This study documents the presence of TNF-a, IL-1J3 and
IL-2R by immunocytochemistry, polymerase chain reaction
and in situ hybridization in the kidneys of patients with ANCA-
positive systemic vasculitis. The demonstration of these factors
at the mRNA and at the protein level points to a local produc-
tion and suggests an important role of these mediators in the
immunopathogenesis of vasculitis.
Infiltrating cells immunoreactive for TNF-a, IL- 1/3 and IL-2R
were found in the majority of the cases, particularly in patients
with active lesions. The positive cells were detected not only in
the interstitium but also in periglomerular and perivascular
sites. In addition, positive cells were present in glomerular
crescents and surrounding tuft necrosis. Staining patterns of
TNF-c and IL-l/3 positive cells were very similar and both
cytokines seemed to be predominantly produced by cells of the
monocyte-macrophage lineage when comparing with sections
stained for CD68. In contrast, the IL-2R positive cells were
smaller, of the lymphocytic type and predominantly expressed
CD3. They were scattered throughout the interstitium but also
present in crescents and periglomerular location.
The evaluation of cytokine expression at the mRNA level
was assessed by RT/PCR and by in situ hybridization. In all six
cases analyzed by PCR, specific transcripts for TNF-a and
IL-113 were detected. One of the great advantages of PCR is the
sensitivity of this method. It may be employed in situations
where the availability of human biopsy material is limited.
Thus, our study documents the feasibility of using one single
frozen biopsy specimen for immunocytochemistry, in situ hy-
bridization and PCR technique. Based on the specificity of in
situ experiments and the correlation with PCR results, we
4
Fig. 9. Results of cytokine mRNA expression in renal biopsies
analyzed by RT/PCR using specific TNF-a (A), IL-I /3 (B) and 3-actin(C) primers. The upper part of the figure shows ethidium bromide
staining of the PCR products separated in 2% agarose gel. The
expected size of PCR-fragments is indicated in base pairs (bp). The
left lane corresponds to a molecular marker weight (DNA molecular
weight marker VI, pBR 328 DNA/Bgl I-Hinf I, 12 fragments, 2.1 to
0.15 kb; Boehringer Mannheim, Germany) and lane 1 represents a
positive control. Lanes 2 to 7 correspond to RNA obtained from
renal biopsies of six different patients. The lower part of the figure
shows the respective Southern blot hybridization analysis of the
cytokine products. TNF-a (Lane A) and /3-actin transcripts were
observed in all cases. IL-1f3 transcripts (Lane B) were detected in all
cases by Southern blot hybridization even if no PCR products were
present when analyzed in agarose gel electrophoresis.
conclude that in biopsies of patients with ANCA-positive
systemic vasculitis there is marked expression of mRNA for
TNF-a and IL-l/3. These results complement the work of
Deguchi et a! [28J who analyzed peripheral blood mononuclear
cells from patients with WG and demonstrated an increased
TNF-a gene expression with the use of a nuclear run on
transcription assay.
By analyzing serial sections, we observed a strong correla-
tion between TNF-a and IL-l/3 mRNA expression and the
immunodetection of cells positive for TNF-a and IL-1f3. We
were not able to demonstrate that the same cell expressing
cytokine mRNA also stained for the protein by simultaneous in
situ hybridization and immunohistochemistry. However, on the
basis of the above arguments, we feel confident that local
production of cytokines occurs. This would be in line with the
hypothesis that cytokines are important mediators in the vas-
culitic process. We observed similar cytokine reactivity in other
forms of inflammatory renal disease such as acute allograft
rejection [25] and lupus nephritis (manuscript in preparation).
The cytokine pattern and the localization of positive cells,
however, showed some differences from that observed in
ANCA-positive GN.
Monocytes/macrophages seem to be the major source of
TNF-c and IL-I /3. Proliferating capsular epithelial cells, how-
ever, also contribute to cytokine production in situ. It is
tempting to speculate, therefore, that these factors may be
involved in the development of the crescents. In contrast to
previous experimental studies [36], it should be pointed out that
we did not find mRNA for TNF-a and IL-l/3 in mesangial areas.
Furthermore, no immunoreactivity for TNF-a and IL- 1/3 was
detected in the mesangium. Endothelial and vascular smooth
muscle cells can also, to a minor degree, be responsible for the
production of these factors in situ. Focal positivity of TNF-a
and IL-1f3 was found in tubular epithelial cells. The demonstra-
tion by both in situ hybridization and immunocytochemistry
largely excludes false positive findings resulting from nonspe-
cific tubular staining or from tubular reabsorption of filtered
cytokines. Whether cytokine production by tubular epithelial
cells plays a pathophysiological role in the development of
tubulointerstitial lesions is presently unclear, but it does de-
serve further investigation.
Further evidence for widespread production of cytokines in
renal and/or extrarenal sites is provided by the observation of
elevated plasma levels of TNF-a and sIL-2R in patients with
ANCA-positive systemic vasculitis at the time of renal biopsy.
Cytokines in blood could be related to clinical symptoms
frequently found in these patients, such as fever, malaise,
myalgia and weight loss. We found a correlation between
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TNF-a and sIL-2R levels and activity of renal lesions, in
agreement with the results reported by Gross and colleagues in
a smaller number of patients [9]. All patients had a marked
increase in sIL-2R plasma levels compared to healthy controls.
IL-l/3 plasma levels were not detectable in the majority of the
plasma samples. Similar findings were reported by Grau and
colleagues [37]. Using RIA they demonstrated moderately
elevated TNF-a levels in three cases of active WG but were
unable to detect IL-1f3. Although TNF-c and sIL-2R plasma
levels in patients in whom treatment had been started prior to
renal biopsy were lower than in naive untreated patients, the
levels were still considerably elevated compared to healthy
controls. This is consistent with clinical evidence of persistent
active disease.
Although our data clearly demonstrate that cytokines are
produced in patients with ANCA-positive systemic vasculitis in
situ, the stimuli which induce such synthesis are unknown.
Resting macrophages and lymphocytes do not produce cyto-
kines or express IL-2R. However, these factors are rapidly
produced by mononuclear cells after immunological activation
[38, 391. It is conceivable that the same mechanisms which
trigger systemic vasculitis are also involved in the activation
signal for the production of cytokines. One candidate may be
ANCA, but it is unknown whether their presence represents
only an epiphenomenon or is causally linked to the pathogene-
sis of the disease. Nevertheless, it has been well documented
that ANCA titers correlate with disease activity [1, 5, 8]. Jayne
and coworkers [401 showed that ANCA of the IgG3 isotype
predominates in active vasculitis whereas a switch to IgG2
occurs in remission. This is of particular importance because
the IgG3 subclass activates complement and binds to macro-
phages via Fc receptors. It is likely that macrophages can be
activated through this mechanism. This may explain the marked
cytokine expression in active vasculitis. Infections, particularly
viral infections, are known to trigger vasculitic processes and
may also be involved, at least initially, in inducing cytokine
production.
What are the potential pathogenic roles of cytokines in
ANCA-positive vasculitis? Production of IL-l/3 by macro-
phages was reported in foreign body granulomas [41] and of
IL-lf3 and TNF-a in an experimental model of pulmonary
granuloma formation [42]. It has been suggested that IL-l/3 is
important in the initiation and TNF-a in the maintenance of
these lesions [42]. In the series of renal biopsies analyzed in this
study we did not observe interstitial granulomas but two cases
disclosed a diffuse granulomatous GN with numerous TNF-a
and IL-lf3 positive cells.
TNF-a can directly induce EC damage in vitro. Several
experiments have demonstrated that TNF-a can lead to mor-
phologic changes of EC, inhibits cell growth and may have
direct cytotoxic influences [43—45]. These alterations also occur
in the kidney in vivo. Bertani et al [46] showed that rabbits
injected with TNF-a developed EC lesions in a dose dependent
manner. The EC damage is accompanied by PMN influx and the
deposition of fibrin in glomerular capillaries. However, this
does not appear to be a direct effect of TNF-a on renal EC,
since TNF-s in the absence of PMN did not cause lesions in the
isolated perfused kidney. In addition, rat pulmonary EC cul-
tured in vitro and pretreated with TNF-a did not exhibit signs of
cytotoxicity [47]. However, there was an increased susceptibil-
ity to killing by activated human neutrophils. Similar results
were obtained with EC pretreated with IL-1/3 [47].
In biopsies with cellular crescents and vascular necrosis,
neutrophils are present in these lesions, but cells with preserved
integrity by morphological criteria generally constitute a minor
component of the cellular infiltrate. Thus, an important mech-
anism by which cytokines may mediate tissue damage is acti-
vation of PMN with subsequent increase in phagocytotic and
cytotoxic capacity [48—501. The interaction between TNF-a and
PMN may occur through binding to TNF-receptors [51]. Using
polyclonal antibodies for immunocytochemistry we detected
TNF-receptor expression not only on granulocytes but also in
mononuclear cells and in endothelial cells of renal biopsies from
patients with vasculitis [52]. This expression may be important
in modulating the action of TNF-a. The activation of PMN by
TNF-a can trigger these cells to undergo a respiratory burst.
Consequently, the necrotizing vasculitic lesion probably results
from the release of reactive oxygen radicals [53] and protein-
ases [53, 54]. The fact that PMN are not prominent in the
infiltrate in kidney biopsies does not exclude a pathogenic role
since cells may desintegrate rapidly after leaving toxic reac-
tants. Interestingly, TNF-a does not induce hydrogen peroxide
release from PMN in suspension [55] and, therefore, does not
lead to EC damage [54]. However, TNF-a induces a marked
production of reactive oxygen species when PMN are co-
cultured with EC, suggesting that PMN adherence is necessary
to convert these cells into an activated state [55]. In this context
it is of note that TNF-c and IL-113 are able to induce de novo
expression of leukocyte adhesion molecules on the endothelial
cell surface. These molecules include ICAM-1, ELAM-1
VCAM-l, and possibly other adhesion molecules, facilitating
the adherence of neutrophils, monocytes and lymphocytes
[18-21].
Alternatively, the neutrophils can be activated by other
mechanisms including antibodies such as ANCA. Incubation of
both P-ANCA and C-ANCA with PMN induce the production
of reactive oxygen species, release of superoxide and neutro-
phi! degranulation. It should be pointed out that this response is
markedly enhanced when PMN are pretreated with TNF-a [10].
Furthermore, it was demonstrated that priming of neutrophils
with TNF-a induce a marked expression of ANCA antigens,
such as myeloperoxidase, on the cell surface. The expression of
these target antigens facilitates the interaction with ANCA
antibodies resulting in subsequent PMN activation and degran-
ulation. The possibility of ANCA-mediated EC damage by
TNF-a was demonstrated by Ewert and coworkers in vitro [11].
In addition, they showed that the intensity of EC damage
correlated with the myeloperoxidase antibody concentration.
These findings are of particular importance in cases in which
circulating ANCA are present, supporting the hypothesis that
an ANCA-mediated cytokine dependent process is involved in
the genesis of the vasculitic reaction.
We conclude that the demonstration of TNF-a, IL-l3 and
IL-2R positive cells in renal biopsies from patients with ANCA-
positive systemic vasculitis strongly supports the involvement
of cytokine producing activated mononuclear cells and of a
cell-mediated immune reaction in the pathogenesis of renal
lesions. In situ production of TNF-a and IL-1f3 by infiltrating
cells, proliferating cells of Bowman's capsule, and even by cells
of the vessel wall itself, in association with ANCA, may prime
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PMN, activate EC and promote their interaction leading to the
vasculitic process.
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